Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/belite-bio-inc" target="_blank" data-smartkarma-citation="entities:35842:1" rel="noopener">Belite Bio (BLTE US)</a> shares jumped 383% from its IPO price of $6 (announced in late April). Its lead candidate LBS-008 is in clinical trial for currently untreatable eye diseases.</li>
<li>LBS-008 continues to be well-tolerated. Interim safety and preliminary efficacy data from ongoing two-year phase 2 trial remained positive in Stargardt disease.</li>
<li>Belite is well-funded to commercialize its pipeline. With the progression of the clinical trial and more data readouts, we believe further stream is left in Belite Bio’s share price.</li>
</ul>



Belite Bio (BLTE US) shares jumped 383% from its IPO price of $6 (announced in late April). Its lead candidate LBS-008 is in clinical trial for currently untreatable eye diseases.
LBS-008 continues to be well-tolerated. Interim safety and preliminary efficacy data from ongoing two-year phase 2 trial remained positive in Stargardt disease.
Belite is well-funded to commercialize its pipeline. With the progression of the clinical trial and more data readouts, we believe further stream is left in Belite Bio’s share price.


Belite Bio (BLTE US): Lead Drug Candidate Tapping into Niche Market with Massive Opportunity

United States

Belite Bio, Inc operates as a clinical stage biopharmaceutical drug development company. The Company focuses on developing novel therapeutics targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease, and diabetes. Belite Bio serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Belite Bio (BLTE US): Lead Drug Candidate Tapping into Niche Market with Massive Opportunity

Belite’s lead candidate LBS-008 is targeting unmet market for AMD. With no approved drug for either of the targeted indications, LBS-008 has...

Tina Banerjee